The agency granted $825,000 to Delix Therapeutics to develop a non-hallucinogenic version of lysergic acid diethylamide, or LSD, designed to treat hearing loss. Early data shows the drug could help repair damaged cells in the ear, according to Politico.
Psychedelic treatments for mental illnesses recently hit a snag. In June, an FDA panel recommended against approving MDMA to treat post-traumatic stress disorder. Experts on the panel expressed concerns with the drug, including the fact that its hallucinogenic effects made it difficult to conduct double-blind studies.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
